Plain-English translation of NCT07066657 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing a new experimental medication called (also known as ARR-217) to see if it can help treat advanced cancers, including colorectal, gastric, and pancreatic cancers. Researchers want to find the safest and most effective dose of this medication, and whether it works better when combined with another existing cancer drug called bevacizumab. The medication targets a specific marker on cancer cells called CDH17.
Many patients with advanced cancers that have spread throughout the body don't respond well to standard treatments, or they become unable to tolerate them. This trial exists to explore whether targeting CDH17 with this new medication could offer a new treatment option for people who have run out of other choices.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the new medication either on its own or combined with bevacizumab at a study center. Your doctor will start with a lower dose and gradually increase it to find the safest effective level. You will have regular visits for blood tests, scans to measure your tumors, and check-ins to monitor how you're responding to treatment and any side effects you experience. The trial expects to enroll about 572 participants across multiple centers, and your participation will involve ongoing monitoring of your health and tumor response.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States